作者
Hilary A Robbins, Aida Ferreiro-Iglesias, Tim Waterboer, Nicole Brenner, Mari Nygard, Noemi Bender, Lea Schroeder, Allan Hildesheim, Michael Pawlita, Gypsyamber D'souza, Kala Visvanathan, Hilde Langseth, Nicolas F Schlecht, Lesley F Tinker, Ilir Agalliu, Sylvia Wassertheil-Smoller, Eivind Ness-Jensen, Kristian Hveem, Sara Grioni, Rudolf Kaaks, Maria-Jose Sánchez, Elisabete Weiderpass, Graham G Giles, Roger L Milne, Qiuyin Cai, William J Blot, Wei Zheng, Stephanie J Weinstein, Demetrius Albanes, Wen-Yi Huang, Neal D Freedman, Aimée R Kreimer, Mattias Johansson, Paul Brennan
发表日期
2022/11/11
期刊
Journal of Clinical Oncology
卷号
40
期号
31
页码范围
3613
出版商
American Society of Clinical Oncology
简介
PURPOSE
Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown.
METHODS
We constructed an OPC risk prediction model that integrates (1) relative odds of OPC for HPV16-E6 serostatus and cigarette smoking from the human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3),(2) US population risk factor data from the National Health Interview Survey, and (3) US sex-specific population rates of OPC and mortality.
RESULTS
The nine HPVC3 cohorts included 365 participants with OPC with up to 10 years between blood draw and diagnosis and 5,794 controls. The estimated 10-year OPC risk for HPV16-E6 seropositive males at age 50 years was 17.4%(95% CI, 12.4 to 28.6) and at age 60 years was 27.1%(95% CI, 19.2 to 45.4). Corresponding 5-year risk estimates were 7.3 …
学术搜索中的文章
HA Robbins, A Ferreiro-Iglesias, T Waterboer… - Journal of Clinical Oncology, 2022